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orrent or Torment
rom the Tubules?*
hallenge of the
ardiorenal Connections
ynne Warner Stevenson, MD, FACC,
nju Nohria, MD, FACC,
isa Mielniczuk, MD
oston, Massachusetts
he increasing use of angiotensin-converting enzyme in-
ibitors and beta-blockers has delayed the progression of
nd decreased mortality in heart failure. As more patients
urvive into advanced stages of disease, however, it is
ncreasingly difficult to maintain optimal fluid balance while
reserving renal function. The complexity of cardiorenal
onnections was the subject of recent review by a working
roup of the National Heart, Lung, and Blood Institute (1).
he current study by Paterna et al. (2) in this issue of the
ournal suggests surprising efficacy of a strategy to enhance
oth acute and chronic diuretic response by enhanced
odium intake. This counterintuitive approach underlines
he need for better understanding of factors that regulate
odium and water handling in chronic heart failure.
See page 1997
HANGING VIEW OF CARDIORENAL
ONNECTIONS DURING DISEASE PROGRESSION
he cardiorenal syndrome can be defined narrowly as
orsening renal function limiting diuresis despite obvious
linical volume overload (3). An elevation in creatinine of
.3 mg/dl or proportional rises of 25% during diuresis are
bserved in more than 20% of heart failure hospitalizations
4). Originally described in patients with low ejection
raction, this syndrome is now recognized to occur as often
n patients admitted with heart failure and preserved ejec-
ion fraction, many of whom have hypertension (5), diabe-
es, and impaired baseline renal function. Risk increases
ith longer history of heart failure and high chronic diuretic
oses. Worsening indices of renal function limit symptom-
tic and neurohormonal therapy, lead to longer hospital
tay, and predict higher rate of early rehospitalization and
eath.
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiovascular Division, Brigham and Women’s Hospital, Boston,
assachusetts. Dr. Stevenson is a consultant for Medtronic Inc. and Scios Inc. andd
eceived research support from Medtronic. Dr. Nohria received research support from
cios Inc.A classic conception of the cardiorenal interaction in
eart failure progression begins with a postulated early
eduction in cardiac output that stimulates systemic and
ntrarenal responses to retain fluid and restores cardiac
utput at new circulating volume. This reduction is followed
y a postulated subsequent progression of cardiac dysfunc-
ion that further diminishes cardiac output, impairing renal
lood flow, and further activating responses that decrease
enal function but fail to normalize cardiac output. At the
ate stage of heart failure, the cardiorenal syndrome has been
ttributed to a postulated further decrease in cardiac output
uring aggressive diuresis to relieve symptoms.
Although internally consistent, this conception is dissolv-
ng. In asymptomatic patients with left ventricular dysfunc-
ion, an inability to excrete a volume load precedes any
vidence of diminution in cardiac output (6). It was once
hought that very high filling pressures were necessary to
aintain stroke volume from the dilated ventricle, thus
roviding one explanation for the chronic stimulus for fluid
etention. However, it is now well established that stroke
olume is maximal at near-normal levels of filling pressure
or most patients with chronic dilated heart failure (7).
igher filling pressures cause increasing wall stress, mitral
egurgitation, and eventually pulmonary hypertension and
econdary right ventricular dysfunction. Right-sided con-
estion then compromises food intake and hepatic function,
eading to malnutrition. The fluid retention far exceeds that
eeded for optimal circulatory function. Once thought to be
nly the manifestation of worsening heart failure, fluid
etention may in fact be a major factor responsible for disease
rogression from asymptomatic through late-stage disease (8).
The cardiorenal syndrome at the late stage of disease is
vident in the patient with multiple hospitalizations for
ongestion, with diuresis interrupted each time by increas-
ng levels of creatinine. This diminution in renal function
ften is dismissed as “pre-renal,” with implications that have
ot advanced understanding or therapy. When actually
easured, central cardiac output and estimated renal perfu-
ion pressure usually have not been reduced during diuresis
3,9) but often have improved as the result of forward
edistribution of mitral regurgitant flow. It remains possible
hat complex changes in regional flow distribution may
ccur without changes in vasodilator dosing or calculated
otal vascular resistance.
A fundamental aspect from asymptomatic through late-
tage heart failure may be the establishment of an elevated
olume set point that exceeds that for optimal circulatory
unction (9). Factors involved in this set point include
ardiac output and activation of renin-angiotensin-
ldosterone and sympathetic systems. A role also is assigned
o natriuretic peptides, but the relationship of circulating
evels to the most active peptides and their coupling to
iologic responses is still obscure. Under complex control,
asopressin remains a strong contender as a player in
iuretic resistance in advanced disease, but with high
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June 21, 2005:2004–7 Editorial Commentnter-individual variation. There is also a potential contri-
ution of blunted neural input from atrophied stretch
eceptors in chronically distended atriopulmonary beds,
hich has been well-demonstrated in dog models of chronic
olume overload (10).
In addition to all of the other factors involved, it is likely
hat the cardiorenal interactions will demonstrate strong
nfluence from genetic polymorphisms that affect neurohor-
onal responses and sodium avidity, as has been observed
or hypertension (9). Pre-existing renal impairment accel-
rates disease progression at all stages. Untangling the
ardiorenal syndrome in humans is further complicated
ecause progression has occurred in the milieu of chronic
eurohormonal antagonists and diuretic therapy, which
timulate chronic compensatory responses (11).
IVE SODIUM A CHANCE?
n the contemporary setting, where the cardiorenal syn-
rome occurs in more than 250,000 hospitalizations annu-
lly (12), the current study challenges accepted concepts
bout acute and chronic diuresis (1). Results from this small
ut elegant randomized study of 94 patients hospitalized
ith clinical volume overload suggest that the administra-
ion of sodium may paradoxically treat the sodium-retaining
tate. For acute diuresis, very high doses of furosemide (500
o 1,000 mg) were administered twice daily with either
ypertonic saline or vehicle infusion concomitantly. Patients
eceiving hypertonic saline had greater volume loss and were
ischarged sooner, with better renal function and higher
erum sodium.
During the chronic phase, the higher salt group had a
arget daily sodium intake of 2.8 g compared with 1.8 g in
he control group. Both groups were restricted to 1 liter of
uid intake daily, unlike many patients for whom fluid is
imited to 2 liters daily or not restricted. In the current
tudy, patients were reassessed at one month, at which time
erum B-type natriuretic peptide levels remained lower in
he group with higher sodium intake. Bioimpedance mea-
urements have not been consistently validated for volume
tate in heart failure but were consistent with lower total
ody volume in the higher sodium group. There were 12
eadmissions in 46 patients during one month in the usual
herapy group compared with none for the higher sodium
roup. Longer follow-up with this therapy is available from
previous single-blind study of 107 patients by the same
uthors (13), in which 43 of 54 patients on usual therapy
ere readmitted compared with 25 of 53 patients during a
1-month mean follow-up, and mortality was reduced in
he treated group. The event rates differ markedly between
hese two studies but together suggest that relaxing sodium
estriction to 2.8 g daily while maintaining severe fluid
estriction to 1 liter daily may improve clinical outcomes.
Attempting to place these results into the context of what
s known about cardiorenal connections emphasizes how
ittle is understood in the human model of fluid retention ruring chronic therapy for heart failure. Reviewing the
revious work, Drazner and Palmer (14) provided lucid
peculation about the effects of this novel therapy. For the
cute phase, why does excess saline load facilitate overall
iuresis? The difference between the amounts of sodium
xcreted acutely by the two groups is largely accounted for
y the higher sodium intake of the high sodium group;
herefore, the difference is not in efficacy of sodium excre-
ion. Rather, there was a larger amount of free water loss in
his group. This may relate in part to an acute osmotic effect
f hypertonic saline to increase mobilization of extravascular
uid into the central circulation and renal circulation. Direct
ntratubular effects of sodium flooding may overwhelm the
ostdiuretic NaCl retention and over time may reduce the
iuretic “braking” phenomenon by which fluid escaping past
he ascending limb is captured downstream (11).
Although neurohormone levels were not assayed, they
ay have been suppressed by hypertonic saline. Both
ncreased intravascular volume and greater delivery of so-
ium to the distal tubule should inhibit the renin-
ngiotensin-aldosterone system. Inhibition of aldosterone
elease could explain the lower relative potassium excretion
n the high sodium group. Reduction in angiotensin II levels
ould lead also to a decrease in vasopressin release despite
emporary increase in serum osmolarity. There may also be
small contribution of increased intravascular volume to
timulation of the low-pressure and high-pressure barore-
eptors that inhibit vasopressin release. Decreased levels of
asopressin could reduce the aquaporin channels through
hich water is reabsorbed, leading to the greater free water
xcretion observed. Reduced vasopressin also might also
ecrease compensatory over-expression of the sodium trans-
orter in the ascending limb, which diminishes diuretic
ffect (15). The marked increase in low serum sodium levels
s consistent with vasopressin inhibition.
The 2.8 g/day of the higher sodium group is less than
ost average diets and therefore would still be considered
odium restriction (although higher than the 2-g daily
ecommended to many patients). Mild sodium restriction
learly appears beneficial to lower blood pressure in hyper-
ension and has been assumed beneficial to delay the need
or diuretic therapy in early heart failure. High sodium
ntake has been observed to lessen efficacy of diuretic
herapy once instituted, presumably because of enhanced
istal tubular reabsorption. Should sodium restriction be
ild or severe, and how should it differ for individual
atients as disease progresses? It is often assumed that a
iven intervention or restriction should be intensified if the
ondition progresses, but this has rarely been proven. In
ypertension, a low-sodium diet potentiates the activation
f the sympathetic and renin-angiotensin system and likely
oes the same in heart failure. Perfusion in the upright
osture may be particularly compromised by low sodium
ntake, with associated neurohormonal response. The key
istinction here may be between mild and severe sodium
estriction.
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Editorial Comment June 21, 2005:2004–7Does sodium intake affect serum sodium levels in heart
ailure? Hyponatremia has long been associated with worse
utcome (16), assumed to reflect severe circulatory compro-
ise amenable only to restriction of free water or improve-
ent of the circulatory state. The brief administration of
ypertonic saline in this study was not sufficient to directly
ause a sustained increase in serum sodium levels and
herefore other mechanisms affecting osmolar regulation,
uch as those discussed previously, must be implicated. Is
he increase in chronic sodium intake sufficient to directly
ccount for the trend toward normalization of serum so-
ium levels, or does it again imply improved neurohormonal
egulation? Additionally, the liberalization of chronic so-
ium restriction could promote better nutrition due to wider
ariety of voluntary nutrient intake.
Hyponatremia has multiple adverse consequences in
erms of cardiac and peripheral muscle function, cardiac
hythm and, again, in relation to systemic circulatory inte-
ration. Resolution of hyponatremia is associated with
etter outcomes in heart failure. Serum sodium increased
uring hospitalization but information is not provided
egarding hyponatremia after discharge in either study. As
ith other biomarkers, a therapy that increases serum
odium level cannot necessarily be presumed as favorable as
pontaneous improvement. The legitimacy of a biomarker
hange during therapy requires validation for that specific
ntervention. In the first month of follow-up, the rate of
ospitalization was lower in patients with less sodium
estriction. It remains to be seen in which patients serum
odium concentration can be sustained by increased sodium
ntake and whether this creates or merely identifies patients
ore likely to do well.
ATIENT POPULATIONS
he patients studied had an average age of 74 years, ejection
raction 30%, and systolic blood pressure 146 mm Hg,
imilar to the previous trial (13,17). This population differs
arkedly from heart failure trial populations but is typical of
atients hospitalized with heart failure in the community
17). The study excluded patients with levels of serum
reatinine 2 mg/dl or blood urea nitrogen 60 mg/dl,
hose most likely to have diuretic resistance and worsening
enal function. The boluses of loop diuretics used, 500 to
,000 mg twice daily, are more than twice as high as
ustomarily used during hospitalization, although total daily
oses would be comparable to high-dose continuous infu-
ions. Dosing of chronic diuretics for outpatients is not
escribed. It is possible that the intensity of diuretic therapy
reated an opportunity for protective benefit from higher
odium intake that would not be realized with lower diuretic
oses. Lastly, the volume restriction of 1 liter per day is
arely achieved or even suggested for most patients with
hronic heart failure in the U.S. (18). The liquid taken with
edications would consume much of that meager allot-
ent. It is sometimes said that either sodium or fluid shoulde restricted but rarely both. With more liberal fluid
onsumption, would increased sodium intake have increased
uid retention and hospitalizations?
CCEPTING THE CHALLENGE
espite the restricted relevance of the protocol, this study
aises important questions. There are insufficient data yet to
outinely administer hypertonic saline to heart failure pop-
lations or liberalize oral sodium intake. However, new
pproaches should be enthusiastically considered for pa-
ients with progressive diuretic resistance, recurrent hospi-
alization, or worsening renal function that limits symptom
elief in whom current therapy is failing. New agents under
evelopment include receptor antagonists for vasopressin
nd adenosine (19,20). If successful, these agents would be
tacked on top of current regimens for maintaining fluid
alance. This study indicates the need to challenge our
urrent practice of chronic sodium restriction. We should
lso challenge how we dose diuretics, both acutely and
hronically (11). Should aldosterone antagonists be titrated
p in some patients to achieve primary diuresis? Should
hiazides be used intermittently even before high-dose loop
iuretics are required? When should diuretic resistance or
enal dysfunction trigger the decrease or discontinuation of
ngiotensin-converting enzyme inhibitors? Will nesiritide
mprove diuresis and renal function in some of these
atients (20)? Are there inotropic or other therapies with
dverse effects that might nonetheless have overall benefit
or some patients if they allow reduction in diuretic therapy?
ey to a better understanding of these questions is the
stablishment of more routine quantitation of circulating
olume, sodium, and water excretion and neurohormonal
esponses acutely and chronically during intervention.
The cardiorenal syndromes are consuming an increasing
roportion of attention and resources for the management
f heart failure. As the lightening threat of sudden death
essens, the clouds darken with the limitations of current
herapy to maintain freedom from congestion while preserv-
ng renal function. Sodium administration alone is not likely
o prevent or solve this problem, but the intriguing obser-
ations from this study provide direction for physiologic
nvestigation and hopefully new strategies.
eprint requests and correspondence: Dr. Lynne Warner
tevenson, Cardiovascular Division, Brigham and Women’s Hos-
ital, 75 Francis Street, Boston, Massachusetts 02115.
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